Lundbeck A/S
Lundbeck A/S
1,00 %
242,20 DKK
2,40
Kurs
242,20
Hög
244,70
Förändring
1,00 %
Låg
240,60
Uppdaterad
13:12:51
Öppen
241,30
Factsheet for Lundbeck A/S
Company Profile
Description
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs worldwide, including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, and Onfi for epilepsy.
Key Stats
Website: http://www.lundbeck.com
Headquarter country: Denmark
Employees: 5 379
Market Cap (at close 21-08-2019): DKK 49B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 14,90 24,40 198,10 51,90 48,00
Forward Price/Earnings 14,40 16,20 48,10 69,00 43,70
Price/Free Cash Flow 11,20 19,40 23,30 420,10 40,20
Return on Assets 18,30 13,10 5,80 -24,20 -0,60
Return on Equity 29,60 24,00 13,10 -51,00 -1,10
Return on Invested Capital 29,40 22,70 10,70 -37,70 1,60
Dividend


Dividend/Share:8,00
Ex. Dividend Date:2018-12-31
Trailing Dividend Yield:5,00
Payout Ratio:70,30
Date Currency Amount
2019-03-31 DKK 12,00
2018-03-31 DKK 8,00
2017-03-31 DKK 2,45
2014-03-31 DKK 2,77
2013-03-31 DKK 2,00
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 18 117,00 17 234,00 15 634,00 14 594,00 13 468,00
Gross Profit 14,66 13,35 11,55 9,20 9,31
Gross Margin % 80,92% 77,48% 73,89% 63,03% 69,11%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 5 301,00 4 591,00 4 018,00 498,00 409,00
Net income 3 907,00 2 624,00 1 211,00 -5 694,00 -153,00
Basic Earnings Per Share 19,66 13,28 6,14 -28,98 -0,78
Operating Income 5,30 4,17 2,29 -6,82 0,10
Operating Margin % 29,26% 24,17% 14,66% -46,70% 0,74%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow 5 981,00 4 045,00 3 126,00 197,00 1 610,00
Capital Expenditures -704,00 -725,00 -342,00 -2 956,00 -1 549,00
Free Cash Flow 5 277,00 3 320,00 2 784,00 -2 759,00 61,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 11 649,00 8 844,00 7 524,00 7 660,00 9 386,00 11 363,00
Long Term Assets 11 362,00 10 912,00 12 686,00 13 665,00 16 251,00 12 286,00
Total Assets 23 011,00 19 756,00 20 210,00 21 325,00 25 637,00 23 649,00
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 7 576,00 6 479,00 7 776,00 7 748,00 7 202,00 6 518,00
Long Term Liabilities 1 096,00 2 740,00 4 792,00
Total Liabilities 7 575,00 10 516,00 12 540,00
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings 12 507,00 10 170,00 7 772,00 6 296,00 11 898,00 12 694,00
Treasury Stock
Total Stockholder Equity 14 251,00 12 181,00 9 694,00 8 785,00 13 526,00 13 481,00
Net Tangible Assets 6 228,00 4 616,00 855,00 -1 009,00 856,00 4 404,00